{
    "clinical_study": {
        "@rank": "114382", 
        "arm_group": [
            {
                "arm_group_label": "Participants with renal impairment", 
                "arm_group_type": "Experimental", 
                "description": "Participants with severe renal impairment will receive a single dose of GS-5816."
            }, 
            {
                "arm_group_label": "Participants with normal renal function", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants with normal renal function will receive a single dose of GS-5816."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the single-dose pharmacokinetics (PK), safety, and tolerability of\n      GS-5816 in participants with severe renal impairment using matched healthy participants as a\n      control group."
        }, 
        "brief_title": "Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C Virus", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  General good health with stable chronic kidney disease in Severe Renal Impairment\n             Group\n\n          -  Screening labs within defined thresholds\n\n          -  Creatinine clearance must be < 30 mL/min for Severe Renal Impairment group, and \u2265 90\n             mL/min for  Normal Renal Function group\n\n        Exclusion Criteria:\n\n          -  Females who are pregnant or nursing, or males who have a pregnant partner\n\n          -  Infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV\n\n          -  History of clinically significant illness (including psychiatric or cardiac) or any\n             other medical disorder that may interfere with subject treatment and/or adherence to\n             the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002767", 
            "org_study_id": "GS-US-281-1056", 
            "secondary_id": "2013-004113-41"
        }, 
        "intervention": {
            "arm_group_label": [
                "Participants with renal impairment", 
                "Participants with normal renal function"
            ], 
            "description": "GS-5816 100 mg (2 x 50 mg tablets) administered orally", 
            "intervention_name": "GS-5816", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Paul", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55114"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Christchurch", 
                        "country": "New Zealand", 
                        "zip": "08011"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "New Zealand"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment", 
        "overall_contact": {
            "email": "Karim.Sajwani@gilead.com", 
            "last_name": "Gilead Study Team"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Luisa Stamm, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "New Zealand: Standing Committee on Therapeutic Trials - (SCOTT)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "AUClast is defined as the concentration of drug from time zero to the last observable concentration\nAUCinf is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time)\nCmax is defined as the maximum concentration of drug", 
            "measure": "Plasma pharmacokinetics (PK) parameters of GS-5816 as measured by AUClast, AUCinf, and Cmax", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Day 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002767"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The incidence of adverse events will be summarized.", 
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 6 plus 30 days"
            }, 
            {
                "description": "Information on vital signs, including electrocardiograms (ECGs), will be collected and summarized.", 
                "measure": "Measurement of vital signs", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 6 plus 30 days"
            }, 
            {
                "description": "The incidence of laboratory abnormalities will be summarized.", 
                "measure": "Incidence of laboratory abnormalities", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 6 plus 30 days"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}